ReviewBiomedicines2021
Nonalcoholic Fatty Liver Disease and the Kidney: A Review.
Review in Biomedicines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association between metabolic dysfunction-associated steatotic liver disease/non-alcoholic fatty liver disease and chronic kidney disease: a systematic review and meta-analysis.Reviews in endocrine & metabolic disorders · 2026Pooled it
- Effects of Non-Alcoholic Fatty Liver Disease on the Inpatient Outcomes of Patients Admitted for Atrial Fibrillation: An Analysis from the National Inpatient Sample Database (NIS 2016-2019).Journal of cardiovascular development and disease · 2026Article
- Investigating Factors Influencing Disease Progression in Patients With Non-Alcoholic Fatty Liver Disease.Journal of clinical medicine research · 2026Article
- Therapeutic Potential of Saikosaponins in MASLD and Cross-Organ Protection: A Research Update.Food science & nutrition · 2026Review
- Hepatokine fibrinogen-like protein 1 drives liver-kidney crosstalk to promote renal fibrosis.Nature communications · 2026Article
- Cross-sectional and longitudinal associations between fatty liver index and kidney function using updated MASLD and CKD-EPI 2021 definitions: a population-based study with region-specific cutoffs.European journal of medical research · 2025Article
- Oxidative stress and inflammation in hemodialysis: a comparison of patients with or without advanced nonalcoholic fatty liver disease (NAFLD).Renal failure · 2025Article
- Distinct Gut Microbiome Signatures in Hemodialysis and Kidney Transplant Populations.Journal of clinical medicine · 2025Article
- Association between serum albumin to creatinine ratio and non-alcoholic fatty liver disease: a longitudinal cohort study in non-obese Chinese individuals.BMC gastroenterology · 2025Article
- From Liver to Kidney: The Overlooked Burden of Nonalcoholic Fatty Liver Disease in Chronic Kidney Disease.Journal of clinical medicine · 2025Review
- Alpha-1 antitrypsin deficiency and Pi*Z allele as important co-factors in the development of liver fibrosis.World journal of hepatology · 2024Article
- New perspectives on the therapeutic potential of quercetin in non-communicable diseases: Targeting Nrf2 to counteract oxidative stress and inflammation.Journal of pharmaceutical analysis · 2024Review
- Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases.Frontiers in cell and developmental biology · 2024Review
- Serum Phosphorus, Serum Bicarbonate, and Renal Function in Relation to Liver CYP1A2 Activity.Diagnostics (Basel, Switzerland) · 2023Article
- Metabolic Syndrome but Not Fatty Liver-Associated Genetic Variants Correlates with Glomerular Renal Function Decline in Patients with Non-Alcoholic Fatty Liver Disease.Biomedicines · 2022Article
- Decrease in Sleep Duration and Poor Sleep Quality over Time Is Associated with an Increased Risk of Incident Non-Alcoholic Fatty Liver Disease.Journal of personalized medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is associated with several extrahepatic manifestations such as cardiovascular disease and sleep apnea. Furthermore, NAFLD is reported to be associated with an increased risk of incident chronic kidney disease (CKD). Inflammation and oxidative stress are suggested to be the key factors involved in the inflammatory mechanisms and pathways linking NAFLD to CKD and are responsible for both the pathogenesis and the progression of CKD in NAFLD patients. This review aims to provide a more comprehensive overview of the association between CKD and NAFLD, also considering the effect of increasing severity of NAFLD. A PubMed search was conducted using the terms "non-alcoholic fatty liver disease AND kidney". In total, 537 articles were retrieved in the last five years and 12 articles were included in the qualitative analysis. Our results showed that CKD developed more frequently in NAFLD patients compared to those without NAFLD. This association persisted after adjustment for traditional risk factors and according to the severity of NAFLD. Therefore, patients with NAFLD should be considered at high risk of CKD. Intensive multidisciplinary surveillance over time is needed, where hepatologists and nephrologists must act together for better and earlier treatment of NAFLD patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.